Abbvie Acquires Djs Antibodies, Further Strengthening Immunology Pipeline Abbvie News Center
This raises the question relating to regardless of whether a decentralized and more open R&D organization that accesses extra competencies, abilities and technologies from external sources could be a measure to enhance the R&D efficiency. Zymeworks’ lead product candidate, zanidatamab, is a HER2-targeted bispecific antibody created employing Zymeworks proprietary Azymetric™ platform. But there’s a reason digital medicine and even a lot more especially, digital therapeutics exist in a subcategory of their own. A digital therapeutic is normally described as an…